| Name |
Indication |
Phase |
SF1126
PI3K Inhibitor Conjugate |
Prostate, breast, ovarian, renal, multiple myeloma, and other solid & hematological cancers PI3K pathway dependent |
Phase I Clinical Trials |
2nd Generation
PI3K small-molecule inhibitors |
Cancer, inflammation, and other indications |
Lead Optimization |
| PTEN Inhibitors & Agonists |
Cancer, cell protection, therapeutic angiogenesis |
Lead Optimization |
2nd Generation
PI3K Inhibitor Conjugates |
Hematological cancers; cancers metastasized to bone |
Discovery |